Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation

Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival. The purpose of our study was to show how of early response to bortezomib combined chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ho Sup, Kim, Yang Soo, Kim, Kihyun, Kim, Jin Seok, Kim, Hyo Jung, Min, Chang-Ki, Suh, Cheolwon, Eom, Hyeon-Seok, Yoon, Sung-Soo, Lee, Jae Hoon, Kim, Min Kyong, Kim, Sung-Hyun, Bae, Sung Hwa, Mun, Yeung-Chul, Jo, Deog Yeon, Chung, Joo-Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546109/
https://www.ncbi.nlm.nih.gov/pubmed/23341716
http://dx.doi.org/10.3346/jkms.2013.28.1.80

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546109/
https://www.ncbi.nlm.nih.gov/pubmed/23341716
http://dx.doi.org/10.3346/jkms.2013.28.1.80

Ejemplares similares